Free Trial
NYSE:KVUE

Kenvue Q2 2025 Earnings Report

Kenvue logo
$20.71 -0.19 (-0.91%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$20.80 +0.09 (+0.43%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kenvue EPS Results

Actual EPS
N/A
Consensus EPS
$0.27
Beat/Miss
N/A
One Year Ago EPS
N/A

Kenvue Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.94 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kenvue Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Kenvue Earnings Headlines

Kenvue Inc. (KVUE) - Yahoo Finance
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Kenvue Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kenvue? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kenvue and other key companies, straight to your email.

About Kenvue

Kenvue (NYSE:KVUE) (NYSE:KVUE) is a global consumer health company that was established in 2023 following its separation from Johnson & Johnson. The company houses a portfolio of well-known over-the-counter and personal care brands, carrying forward a legacy that spans more than a century of innovation in health and wellness. With its headquarters in New Brunswick, New Jersey, Kenvue began independent trading as part of a strategic move to focus solely on consumer health products while leveraging the deep brand equity and research capabilities inherited from its predecessor.

The company’s product offerings span several core categories, including pain relief, skin health, oral care, baby care and women’s health. Signature brands under the Kenvue umbrella include Tylenol, Neutrogena, Aveeno, Listerine and Johnson’s Baby. Kenvue’s portfolio also encompasses digestive health solutions and nutritional supplements, backed by a focus on science-driven formulation and consumer-focused innovation. Research and development efforts target both the enhancement of existing product lines and the introduction of new offerings that address emerging health and wellness trends.

Operating in more than 100 countries, Kenvue employs a multi-channel distribution strategy that includes retail pharmacies, mass merchandisers, grocery chains and e-commerce platforms. The company’s global supply chain is supported by manufacturing facilities and partnerships across North America, Europe, Asia-Pacific and Latin America. Kenvue places emphasis on expanding access to affordable healthcare products in emerging markets while optimizing its footprint in established markets through sustainable sourcing and packaging initiatives.

Leadership at Kenvue is headed by Chief Executive Officer Thibaut Mongon, whose background in consumer products and healthcare drives the company’s strategic direction. The senior management team brings decades of combined experience in brand management, product innovation and global operations. Kenvue’s governance framework emphasizes environmental, social and corporate responsibility, with objectives that include reducing carbon emissions, enhancing supply chain transparency and supporting community health programs worldwide.

View Kenvue Profile

More Earnings Resources from MarketBeat